- Fee assured
- Verified this account
You'll need to contact this healthcare professional to check their availability
Rehna Khan is passionate about optimising the clinical care of patients with retinal disease. Rehna has been teaching and mentoring junior doctors for 18 years within the N.H.S and appraising peers and senior colleagues. She has had many leadership positions including principal investigator of multiple national research trials and board member of the North of England Ophthalmological Society and the Yorkshire Retina Society. Rehna has many medical retina publications in peer reviewed journals and has a special interest in age related macular degeneration, diabetic retinopathy and retinal vein occlusion.
Areas of interest
age related macular degeneration;
retinal vein occlusion;
Current NHS consultant posts held
Consultant Ophthalmologist, Calderdale & Huddersfield NHS Trust
Mrs. Khan has published peer reviewed papers in medical Retina. She is also regularly invited to deliver lectures at regional ophthalmic meetings.
She has been principal investigator on multiple NIHR portfolio studies.
Mrs Khan is honorary lecturer at Bradford University optometry department.
Shortest set up time (2 months) for new portfolio study prize, 2015.
I led a team that won Royal Society of Medicine prize for original research. June 2015
(Additional) Languages spoken
- Urdu - Fluent
- Pashto, Pushto - Fluent
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy.
Lee CS, Lee AY, Baughman D, Sim D, Akelere T, Brand C, Crabb DP, Denniston AK, Downey L, Fitt A, Khan R, Mahmood S, Mandal K, Mckibbin M, Menon G, Lobo A, Kumar BV, Natha S, Varma A, Wilkinson E, Mitry D, Bailey C, Chakravarthy U, Tufail A, Egan C; UK DR EMR Users Group.
Am J Ophthalmol. 2017 Aug;180:64-71.
The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema.
Denniston AK, Chakravarthy U, Zhu H, Lee AY, Crabb DP, Tufail A, Bailey C, Akerele T, Al-Husainy S, Brand C, Downey L, Fitt A, Khan R, Kumar V, Lobo A, Mahmood S, Mandal K, Mckibbin M, Menon G, Natha S, Ong JM, Tsaloumas MD, Varma A, Wilkinson E, Johnston RL, Egan CA; UK DR EMR Users Group.
Br J Ophthalmol. 2017 Dec;101(12):1673-1678.
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, Hamilton R, Khan R, Al-Husainy S, Brand C, Akerele T, Mckibbin M, Downey L, Tufail A.
Br J Ophthalmol. 2017 Dec;101(12):1683-1688.
- MB ChB Liverpool University Medical School 2000
- PG Cert Med ED Staffordshire University 2005
- FRCOphth Royal College of Ophthalmologists 2006
Reference number 4722276
Professional bodies (positions held - last 3 yrs)
- Trustee Yorkshire Retina Society 2010
- Council Member North of England Ophthalmologocal Society 2019
Affiliations / memberships
American Academy of Ophthalmology
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.